

Quality of Physician Communication about HPV Vaccine—Letter

Andrzej Kulczycki¹ and Richard M. Shewchuk²

The United States was first to introduce human papillomavirus (HPV) vaccination but a decade later, despite demonstrated effectiveness and safety, uptake remains lower than in other countries and in comparison with other adolescent vaccines. Numerous factors explain these disparities. The prevailing thinking is that vaccine uptake could be improved by having physicians recommend HPV vaccination according to guidelines. Although physicians are influential in patient decision-making, we suggest that it is overly simplistic to think that their recommendations alone will ensure targeted goals. Given the putative influence of physicians' recommendations in the context of suboptimal HPV vaccine uptake, one might assume that either physicians do not recommend HPV vaccination, or how they communicate recommendations is not acceptable to patients.

In this journal, Gilkey and colleagues (1) recently concluded that instrumental aspects (timeliness, consistency, urgency, strength) of overall vaccination recommendation quality comprise an index reflective of the quality of physician recommendation communications, and implying the use of more prescriptive communications improves HPV vaccination rates. In an accompanying commentary, Zimet lauds this index of overall vaccination quality as a potentially valuable tool for use in interventions to promote HPV vaccination (2). The intention of this study is commendable, but we believe it conflates instrumental communication practices with overall recommendation quality.

¹Department of Health Care Organization and Policy, University of Alabama at Birmingham, Birmingham, Alabama. ²Department of Health Services Administration, School of Health Professions, University of Alabama at Birmingham, Birmingham, Alabama.

Corresponding Author: Andrzej Kulczycki, University of Alabama at Birmingham, 320 Ryals Public Health Bldg., 1665 University Blvd., Birmingham, AL 35294-0022. Phone: 205-934-9875; Fax: 205-934-3347; E-mail: andrzej@uab.edu

doi: 10.1158/1055-9965.EPI-16-0049

©2016 American Association for Cancer Research.

References

1. Gilkey MB, Malo TL, Shah PD, Hall ME, Brewer NT. Quality of physician communication about human papillomavirus vaccine: findings from a national survey. *Cancer Epidemiol Biomarkers Prev* 2015;24:1673–9.
2. Zimet GD. "A day late and a dollar short": physicians and HPV vaccination. *Cancer Epidemiol Biomarkers Prev* 2015;24:1643–4.
3. Politi MC, Wolin KY, Légaré F. Implementing clinical practice guidelines about health promotion and disease prevention

We agree that physicians' communication of recommendations must be examined, but not from a physician-centered perspective and instead from the perspective of patient–provider shared decision-making that recognizes the principle of informed choice (3). We would argue that any discussion of a recommendation, in addition to the possible inclusion of some of the more instrumental aspects of recommendations, needs to be embedded within this patient-centered discussion. Our ongoing work confirms that many physicians are unable or unwilling to engage in a patient-centered discussion needed to overcome vaccine hesitancy (4). Furthermore, physicians who discuss HPV vaccination with girls ages 11 to 12 and their mothers are more likely to start and sustain vaccine administration. Interestingly, Zimet previously presented work in support of our position that effective communication emphasizes the process of respectful elicitation and responses (5).

The prevailing zeitgeist in health care reform stresses the need for informed decision-making and patient-centeredness. A directive mode of communicating vaccine recommendations may work with infants and toddlers, but not with adolescents. Physicians' HPV vaccination recommendations should be examined in terms of their instrumental quality and also from the perspective of a communication that considers the acceptability of the recommendation for the patient.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Disclaimer

Views expressed herein are those of the authors and do not necessarily reflect those of NIAID or other institutions.

Grant Support

Funding for this study was provided by the National Institute of Allergy and Infectious Diseases (NIAID), grant R03 AI090499 (Principal Investigator: A. Kulczycki).

Received January 26, 2016; accepted January 27, 2016; published online May 2, 2016.

- through shared decision making. *J Gen Intern Med* 2013;28:838–44.
4. Kulczycki A, Qu H, Shewchuk RM. Primary care physicians' adherence to guidelines and their likelihood to prescribe HPV vaccine for 11–12 year-old girls. *Womens Health Issues* 2016;26:34–9.
5. Zimet GD. Improving adolescent health: focus on HPV vaccine acceptance. *J Adolesc Health* 2005;37:S17–S23.